June 22 (Reuters) - The U.S. Food and Drug Administration said on Monday it is launching a series of measures to speed up ...

de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

The US Food and Drug Administration (FDA) is seeking comments on a pilot program where qualified external institutions will ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and the need for new drugs is urgent. In a joint call to action, the ...

Antimicrobial resistance (AMR) is an inevitable evolutionary process — resistance will occur, and it will spread globally. We are in a race to maintain a portfolio of effective antibiotics, and we are ...

Bacterial granular sludge (BGS) efficiently removes antibiotics but acts as a hotspot for the enrichment of antibiotic resistance genes (ARGs). To decouple removal from resistance, we integrated ...